Sponsor Deadline
Posted: 11/15/2023

The Lawrence and Isabel Barnett Drug Development Program

There is an urgent need for new and improved therapies for ALS, as there is still no cure. The Lawrence and Isabel Barnett Drug Development Program seeks to accelerate the availability of new, effective ALS treatments by supporting the preclinical assessment of novel therapies or repositioned treatment approaches in preparation for clinical testing. These 2-year awards with a maximum budget of $500,000 are open to both industry and academic investigators. Applicants should have a development candidate in hand as this funding opportunity aims to support programs that have a high probability of entering the clinic within 3 years. 

Successful applications will include strong and compelling data supporting the biological rationale for the proposed treatment and a clear plan for moving it through the essential stages of development, including essential “go/no-go” decision milestones. Applications should thoroughly describe what is known about pharmacokinetic and pharmacodynamic (PK/PD) relationships, including plans to address any gaps in this understanding. Studies can be performed by a contract research organization in collaboration with the principal investigator (PI). 

Deadline for Letter of Intent: Dec. 18, 2023

Areas of Interest

Both novel programs and repurposing of approved or clinically safe therapies from other disease indications are appropriate for this funding opportunity. We are especially interested in:

• In vivo efficacy testing of therapeutic candidates (pharmacological treatments, biological therapies, or gene therapies) in models of ALS.

• Studies focused on pharmacokinetics, pharmacodynamics, preclinical toxicology/safety (ADME/Tox), dose-range finding, and target engagement.

• Other Investigational New Drug (IND)-enabling studies. 

Eligibility Requirements

Individuals with the skills, knowledge and resources necessary to carry out the proposed research may apply as a principal investigator. Postdoctoral fellows are not eligible to apply as principal investigators. 

Amount Description

Award: $500,000 in total funding over 2 years to support the preclinical assessment of novel or repurposed therapeutics for ALS 

Funding Type